For patients with MDD, individuals who received GeneSight had total costs of $18,741 compared to $24,971 in TAU arm representing total cost savings of $6,050.
“From the perspective of managed care decision makers, as our results indicate, the use of CPGx offers clinicians and their patients the benefit of more precise selection of psychotropic drugs while offering cost savings to the health plan. Moreover, coverage of CPGx may yield material PMPM savings associated with spending on anxiety, depression and bipolar disorder and marginal PMPM savings associated with overall spending on psychiatric disorders. Since the test cost is a one-time investment, average savings are expected to increase as the duration is extended over the life cycle of psychiatric treatment.”
Benitez J, et al. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders: financial impact on a health plan. Per Med 2018 Nov; 15(6):481-94.
Learn More View Article